重症成人万古霉素持续输注与间歇输注对急性肾损伤风险的系统评价与Meta分析
该系统评价与Meta分析纳入11项随机对照试验和观察性研究,评估重症成人中万古霉素持续输注与间歇输注对急性肾损伤的影响。结果显示,持续输注组急性肾损伤的OR为0.47(95%CI 0.34-0.65),药代动力学目标达成的OR为2.63(95%CI 1.52-4.57),死亡率无显著差异(OR 1.04,95%CI 0.80-1.35)。结论提示持续输注可能优化安全性和达标率,但不影响总体死亡率。
要点
- 与间歇输注相比,持续输注万古霉素使重症成人急性肾损伤风险降低53%(OR 0.47,95%CI 0.34-0.65)。
- 与间歇输注相比,持续输注万古霉素使药代动力学目标达成率提高2.6倍(OR 2.63,95%CI 1.52-4.57)。
- 持续输注与间歇输注相比,死亡率无显著差异(OR 1.04,95%CI 0.80-1.35)。
- 该Meta分析共纳入11项研究,对象为接受万古霉素经验性治疗的重症成人。
适用人群与场景
- 重症成人患者,接受万古霉素经验性抗生素治疗。
研究设计与关键结果
- 研究设计为系统评价与Meta分析,纳入11项随机对照试验和观察性研究,比较重症成人中万古霉素间歇输注与持续输注。
- 主要终点急性肾损伤:与间歇输注相比,持续输注的OR为0.47(95%CI 0.34-0.65)。
- 次要终点药代动力学目标达成:与间歇输注相比,持续输注的OR为2.63(95%CI 1.52-4.57)。
- 次要终点死亡率:与间歇输注相比,持续输注的OR为1.04(95%CI 0.80-1.35),无显著差异。
证据类型、等级与局限
- 证据类型:系统评价与Meta分析,纳入随机对照试验和观察性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文未据此给出推荐。
指南或共识出处
- Crit Care Med
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Critically ill patients routinely receive vancomycin as empiric antibiotic therapy. A continuous infusion administration strategy may be superior to intermittent infusion by minimizing peak concentrations and variability thereby optimizing safety. We performed a systematic review and meta-analysis to investigate the impact of vancomycin infusion strategy on acute kidney injury in critically ill adults.
DATA SOURCES: A systematic search of MEDLINE, CINAHL, Web of Science, International Pharmaceutical Abstracts, and Google Scholar was undertaken.
STUDY SELECTION: We included randomized controlled trials and observational studies evaluating acute kidney injury in critically ill adults comparing vancomycin administered by intermittent and continuous infusion. Secondary outcomes included mortality and pharmacokinetic target attainment.
DATA EXTRACTION: Eleven studies were identified for analysis with baseline demographics, endpoints, protocol definitions, and outcomes extracted.
DATA SYNTHESIS: When compared with intermittent infusion, continuous infusion was associated with a reduction in acute kidney injury in critically ill adults (odds ratio, 0.47; 95% CI, 0.34-0.65) and a 2.6 greater odds of pharmacokinetic target attainment (odds ratio, 2.63; 95% CI, 1.52-4.57). No difference in mortality was observed (odds ratio, 1.04; 95% CI, 0.80-1.35).
CONCLUSIONS: When administered via a continuous infusion, vancomycin is associated with a 53% reduction in the odds of acute kidney injury and a 2.6-fold higher odds of pharmacokinetic target attainment when compared with intermittent infusion without influencing overall mortality.
参考来源
- Flannery AH, Bissell BD, Bastin MT, et al. Continuous Versus Intermittent Infusion of Vancomycin and the Risk of Acute Kidney Injury in Critically Ill Adults: A Systematic Review and Meta-Analysis. Crit Care Med. 2020. PMID: 32317590. doi:10.1097/CCM.0000000000004326
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。